journal
https://read.qxmd.com/read/36440584/nlrp3-inflammasome-activation-through-heart-brain-interaction-initiates-cardiac-inflammation-and-hypertrophy-during-pressure-overload
#1
JOURNAL ARTICLE
Yasutomi Higashikuni, Wenhao Liu, Genri Numata, Kimie Tanaka, Daiju Fukuda, Yu Tanaka, Yoichiro Hirata, Teruhiko Imamura, Eiki Takimoto, Issei Komuro, Masataka Sata
BACKGROUND: Mechanical stress on the heart, such as high blood pressure, initiates inflammation and causes hypertrophic heart disease. However, the regulatory mechanism of inflammation and its role in the stressed heart remain unclear. IL-1β (interleukin-1β) is a proinflammatory cytokine that causes cardiac hypertrophy and heart failure. Here, we show that NLRP3 (neural signals activate the nucleotide-binding domain, leucine-rich-containing family, pyrin domain-containing 3) inflammasome for IL-1β production to induce adaptive hypertrophy in the stressed heart...
November 28, 2022: Circulation
https://read.qxmd.com/read/36440577/lipoprotein-a-in-youth-and-prediction-of-major-cardiovascular-outcomes-in-adulthood
#2
JOURNAL ARTICLE
Olli Raitakari, Noora Kartiosuo, Katja Pahkala, Nina Hutri-Kähönen, Lydia A Bazzano, Wei Chen, Elaine M Urbina, David R Jacobs, Alan Sinaiko, Julia Steinberger, Trudy Burns, Stephen R Daniels, Alison Venn, Jessica G Woo, Terry Dwyer, Markus Juonala, Jorma Viikari
BACKGROUND: Elevated lipoprotein(a) [Lp(a)] is a common risk factor for cardiovascular disease outcomes with unknown mechanisms. We examined its potential role in identifying youths who are at increased risk of developing adult atherosclerotic cardiovascular disease (ASCVD). METHODS: Lp(a) levels measured in youth 9 to 24 years of age were linked to adult ASCVD and carotid intima-media thickness in the YFS (Cardiovascular Risk in Young Finns Study), in which 95 of the original 3596 participants (2...
November 28, 2022: Circulation
https://read.qxmd.com/read/36420731/metabolic-changes-associated-with-cardiomyocyte-dedifferentiation-enable-adult-mammalian-cardiac-regeneration
#3
JOURNAL ARTICLE
Yuan-Yuan Cheng, Zachery Gregorich, Ray P Prajnamitra, David J Lundy, Ting-Yun Ma, Yu-Hsuan Huang, Yi-Chan Lee, Shu-Chian Rua, Jen-Hao Lin, Po-Ju Lin, Chiung Wen Kuo, Peilin Chen, Yu-Ting Yan, Rong Tian, Timothy J Kamp, Patrick C H Hsieh
BACKGROUND: Cardiac regeneration after injury is limited by the low proliferative capacity of adult mammalian cardiomyocytes (CMs). However, certain animals readily regenerate lost myocardium through a process involving dedifferentiation, which unlocks their proliferative capacities. METHODS: We bred mice with inducible, CM-specific expression of the Yamanaka factors, enabling adult CM reprogramming and dedifferentiation in vivo. RESULTS: Two days after induction, adult CMs presented a dedifferentiated phenotype and increased proliferation in vivo...
November 24, 2022: Circulation
https://read.qxmd.com/read/36417924/circulating-c-met-expressing-memory-t-cells-define-cardiac-autoimmunity
#4
JOURNAL ARTICLE
Silvia Fanti, Edward Stephenson, Etel Rocha-Vieira, Alexandros Protonotarios, Stavroula Kanoni, Eriomina Shahaj, M Paula Longhi, Vishal S Vyas, Carlene Dyer, Elena Pontarini, Angeliki Asimaki, Carlos Bueno-Beti, Monica De Gaspari, Stefania Rizzo, Cristina Basso, Michele Bombardieri, David Coe, Guosu Wang, Daniel Harding, Iain Gallagher, Egle Solito, Perry Elliott, Stephane Heymans, Maurits Sikking, Konstantinos Savvatis, Saidi A Mohiddin, Federica M Marelli-Berg
BACKGROUND: Autoimmunity is increasingly recognized as a key contributing factor in heart muscle diseases. The functional features of cardiac autoimmunity in humans remain undefined because of the challenge of studying immune responses in situ. We previously described a subset of c-mesenchymal epithelial transition factor (c-Met)-expressing (c-Met+ ) memory T lymphocytes that preferentially migrate to cardiac tissue in mice and humans. METHODS: In-depth phenotyping of peripheral blood T cells, including c-Met+ T cells, was undertaken in groups of patients with inflammatory and noninflammatory cardiomyopathies, patients with noncardiac autoimmunity, and healthy controls...
November 23, 2022: Circulation
https://read.qxmd.com/read/36416142/macrophage-derived-25-hydroxycholesterol-promotes-vascular-inflammation-atherogenesis-and-lesion-remodeling
#5
JOURNAL ARTICLE
Alberto Canfrán-Duque, Noemi Rotllan, Xinbo Zhang, Irene Andrés-Blasco, Bonne M Thompson, Jonathan Sun, Nathan L Price, Marta Fernández-Fuertes, Joseph W Fowler, Diego Gómez-Coronado, William C Sessa, Chiara Giannarelli, Robert J Schneider, George Tellides, Jeffrey G McDonald, Carlos Fernández-Hernando, Yajaira Suárez
BACKGROUND: Cross-talk between sterol metabolism and inflammatory pathways has been demonstrated to significantly affect the development of atherosclerosis. Cholesterol biosynthetic intermediates and derivatives are increasingly recognized as key immune regulators of macrophages in response to innate immune activation and lipid overloading. 25-Hydroxycholesterol (25-HC) is produced as an oxidation product of cholesterol by the enzyme cholesterol 25-hydroxylase (CH25H) and belongs to a family of bioactive cholesterol derivatives produced by cells in response to fluctuating cholesterol levels and immune activation...
November 23, 2022: Circulation
https://read.qxmd.com/read/36384284/targeting-vegf-a-vegfr2-y949-signaling-mediated-vascular-permeability-alleviates-hypoxic-pulmonary-hypertension
#6
JOURNAL ARTICLE
Weibin Zhou, Keli Liu, Lei Zeng, Jiaqi He, Xinbo Gao, Xinyu Gu, Xun Chen, Jing Jing Li, Minghui Wang, Duoguang Wu, Zhixiong Cai, Lena Claesson-Welsh, Rong Ju, Jingfeng Wang, Feng Zhang, Yangxin Chen
BACKGROUND: Pulmonary hypertension (PH) is associated with increased expression of VEGF-A (vascular endothelial growth factor A) and its receptor, VEGFR2 (vascular endothelial growth factor 2), but whether and how activation of VEGF-A signal participates in the pathogenesis of PH is unclear. METHODS: VEGF-A/VEGFR2 signal activation and VEGFR2 Y949-dependent vascular leak were investigated in lung samples from patients with PH and mice exposed to hypoxia. To study their mechanistic roles in hypoxic PH, we examined right ventricle systolic pressure, right ventricular hypertrophy, and pulmonary vasculopathy in mutant mice carrying knock-in of phenylalanine that replaced the tyrosine at residual 949 of VEGFR2 ( Vefgr2 Y949F ) and mice with conditional endothelial deletion of Vegfr2 after chronic hypoxia exposure...
November 17, 2022: Circulation
https://read.qxmd.com/read/36382596/cardiac-troponin-i-interacting-kinase-impacts-cardiomyocyte-s-phase-activity-but-not-cardiomyocyte-proliferation
#7
JOURNAL ARTICLE
Sean P Reuter, Mark H Soonpaa, Dorothy Field, Ed Simpson, Michael Rubart-von der Lohe, Han Kyu Lee, Arthi Sridhar, Stephanie M Ware, Nick Green, Xiaochun Li, Susan Ofner, Douglas A Marchuk, Kai C Wollert, Loren J Field
BACKGROUND: Identifying genetic variants which impact the level of cell cycle reentry and establishing the degree of cell cycle progression in those variants could help guide development of therapeutic interventions aimed at effecting cardiac regeneration. We observed that C57Bl6/NCR (B6N) mice have a marked increase in cardiomyocyte S-phase activity following permanent coronary artery ligation as compared to infarcted DBA/2J (D2J) mice. METHODS: Cardiomyocyte cell cycle activity post-infarction was monitored in D2J, (D2J x B6N)-F1 and [(D2J x B6N)-F1 x D2J] backcross mice via bromodeoxyuridine or 5-ethynyl-2' -deoxyuridine incorporation, using a nuclear-localized transgenic reporter to identify cardiomyocyte nuclei...
November 16, 2022: Circulation
https://read.qxmd.com/read/36382595/do-we-need-ischemia-testing-to-monitor-asymptomatic-patients-with-chronic-coronary-syndromes
#8
JOURNAL ARTICLE
Philippe Gabriel Steg, John Kikoïne
No abstract text is available yet for this article.
November 16, 2022: Circulation
https://read.qxmd.com/read/36373541/an-overview-of-telehealth-in-the-management-of-cardiovascular-disease-a-scientific-statement-from-the-american-heart-association
#9
REVIEW
Edwin A Takahashi, Lee H Schwamm, Opeolu M Adeoye, Olamide Alabi, Eiman Jahangir, Sanjay Misra, Carolyn H Still
Telehealth enables the remote delivery of health care through telecommunication technologies and has substantially affected the evolving medical landscape. The COVID-19 pandemic accelerated the utilization of telehealth as health care professionals were forced to limit face-to-face in-person visits. It has been shown that information delivery, diagnosis, disease monitoring, and follow-up care can be conducted remotely, resulting in considerable changes specific to cardiovascular disease management. Despite increasing telehealth utilization, several factors such as technological infrastructure, reimbursement, and limited patient digital literacy can hinder the adoption of remote care...
November 14, 2022: Circulation
https://read.qxmd.com/read/36342827/empagliflozin-in-black-versus-white-patients-with-heart-failure-analysis-of-emperor-pooled
#10
LETTER
Subodh Verma, Nitish K Dhingra, Javed Butler, Stefan D Anker, João Pedro Ferreira, Gerasimos Filippatos, James L Januzzi, Carolyn S P Lam, Naveed Sattar, Egon Pfarr, Matias Nordaby, Martina Brueckmann, Stuart J Pocock, Faiez Zannad, Milton Packer
No abstract text is available yet for this article.
November 7, 2022: Circulation
https://read.qxmd.com/read/36342823/incidental-coronary-artery-calcium-opportunistic-screening-of-prior-non-gated-chest-cts-to-improve-statin-rates-notify-1-project
#11
JOURNAL ARTICLE
Alexander T Sandhu, Fatima Rodriguez, Summer Ngo, Bhavik N Patel, Domenico Mastrodicasa, David Eng, Nishith Khandwala, Sujana Balla, Doug Sousa, David J Maron
BACKGROUND: Coronary artery calcium (CAC) can be identified on non-gated chest CTs, but this finding is not consistently incorporated into care. A deep learning algorithm enables opportunistic CAC screening of non-gated chest CTs. Our objective was to evaluate the impact of notifying clinicians and patients of incidental CAC on statin initiation. METHODS: NOTIFY-1 was a randomized quality improvement project in the Stanford healthcare system. Patients without known atherosclerotic cardiovascular disease (ASCVD) or prior statin prescription were screened for CAC on a prior non-gated chest CT from 2014-2019 using a validated deep learning algorithm with radiologist confirmation...
November 7, 2022: Circulation
https://read.qxmd.com/read/36342789/sex-differences-in-characteristics-outcomes-and-treatment-response-with-dapagliflozin-across-the-range-of-ejection-fraction-in-patients-with-heart-failure-insights-from-dapa-hf-and-deliver
#12
JOURNAL ARTICLE
Xiaowen Wang, Muthiah Vaduganathan, Brian L Claggett, Sheila M Hegde, Maria Pabon, Ian J Kulac, Orly Vardeny, Eileen O'Meara, Shelley Zieroth, Tzvetana Katova, Martina M McGrath, Anne-Catherine Pouleur, Pardeep S Jhund, Akshay S Desai, Silvio E Inzucchi, Mikhail N Kosiborod, Rudolf A de Boer, Lars Køber, Marc S Sabatine, Felipe A Martinez, Piotr Ponikowski, Sanjiv J Shah, Adrian F Hernandez, Anna Maria Langkilde, John J V McMurray, Scott D Solomon, Carolyn S P Lam
BACKGROUND: Sodium-glucose cotransporter-2 (SGLT2) inhibitors have emerged as a key pharmacotherapy in heart failure (HF) with both reduced and preserved ejection fraction. The benefit of other HF therapies may be modified by sex, but whether sex modifies the treatment effect and safety profile of SGLT2 inhibitors remains unclear. Our analyses aim to assess the impact of sex on the efficacy and safety of dapagliflozin. METHODS: In a pre-specified patient-level pooled analysis of DAPA-HF and DELIVER, clinical outcomes were compared by sex (including the composite of cardiovascular [CV] death or worsening HF events; CV death; all-cause death, total events (first and recurrent HF hospitalization and CV death), and Kansas City Cardiomyopathy Questionnaire [KCCQ] scores) across the spectrum of left ventricular ejection fraction (EF)...
November 7, 2022: Circulation
https://read.qxmd.com/read/36342665/randomized-controlled-trial-of-a-smartphone-based-intervention-to-enhance-six-minute-walk-distance-during-breast-cancer-treatment-the-smart-breast-trial
#13
LETTER
Alexandra C Murphy, Omar Farouque, Anoop N Koshy, Belinda Yeo, Ron Dick, Voltaire Nadurata, Laura Roccisano, Christopher Reid, Matias B Yudi
No abstract text is available yet for this article.
November 7, 2022: Circulation
https://read.qxmd.com/read/36342475/aspirin-vs-clopidogrel-for-chronic-maintenance-monotherapy-after-percutaneous-coronary-intervention-the-host-exam-extended-study
#14
JOURNAL ARTICLE
Jeehoon Kang, Kyung Woo Park, Huijin Lee, Doyeon Hwang, Han-Mo Yang, Seung-Woon Rha, Jang-Whan Bae, Nam Ho Lee, Seung Ho Hur, Jung-Kyu Han, Eun-Seok Shin, Bon-Kwon Koo, Hyo-Soo Kim
Background: Long term outcomes of antiplatelet monotherapy in patients who receive percutaneous coronary intervention (PCI) are unknown. The HOST-EXAM Extended study reports the post-trial follow-up results of the original HOST-EXAM trial. Methods: From March 2014 through May 2018, 5438 patients who maintained dual antiplatelet therapy without clinical events for 12±6 months after PCI with drug-eluting stents (DES) were randomly assigned in a 1:1 ratio to receive clopidogrel 75mg once daily or aspirin 100mg once daily...
November 7, 2022: Circulation
https://read.qxmd.com/read/36342348/exercise-for-the-prevention-of-anthracycline-induced-functional-disability-and-cardiac-dysfunction-the-breast-cancer-randomized-exercise-intervention-brexit-study
#15
JOURNAL ARTICLE
Stephen J Foulkes, Erin J Howden, Mark J Haykowsky, Yoland Antill, Agus Salim, Sophie S Nightingale, Sherene Loi, Piet Claus, Kristel Janssens, Amy M Mitchell, Leah Wright, Ben T Costello, Anniina Lindqvist, Lauren Burnham, Imogen Wallace, Robin M Daly, Steve F Fraser, André La Gerche
Background: Breast cancer (BC) survivors treated with anthracycline-based chemotherapy (AC) have increased risk of functional limitation and cardiac dysfunction. We conducted a 12-month randomized controlled trial in 104 early-stage BC patients scheduled for AC to determine if 12-months of exercise training (ExT) could attenuate functional disability (primary endpoint), improve cardiorespiratory fitness (VO2 peak) and prevent cardiac dysfunction. Methods: Women aged 40-75 years with stage I-III BC scheduled for AC were randomized to 3-4 days/wk of aerobic and resistance ExT for 12-months (n = 52) or usual care ([ UC ], n = 52)...
November 7, 2022: Circulation
https://read.qxmd.com/read/36335920/if-the-fates-allow-the-zero-sum-game-of-ischemia-extend
#16
EDITORIAL
Steven M Bradley, Ty J Gluckman
No abstract text is available yet for this article.
November 6, 2022: Circulation
https://read.qxmd.com/read/36335918/survival-after-invasive-or-conservative-management-of-stable-coronary-disease
#17
JOURNAL ARTICLE
Judith S Hochman, Rebecca Anthopolos, Harmony R Reynolds, Sripal Bangalore, Yifan Xu, Sean M O'Brien, Stavroula Mavromichalis, Michelle Chang, Aira Contreras, Yves Rosenberg, Ruth Kirby, Balram Bhargava, Roxy Senior, Ann Banfield, Shaun G Goodman, Renato D Lopes, Radoslaw Pracon, José López-Sendón, Aldo Pietro Maggioni, Jonathan D Newman, Jeffrey S Berger, Mandeep S Sidhu, Harvey D White, Andrea B Troxel, Robert A Harrington, William E Boden, Gregg W Stone, Daniel B Mark, John A Spertus, David J Maron
Background: The ISCHEMIA trial compared an initial invasive versus an initial conservative management strategy for patients with chronic coronary disease and moderate or severe ischemia, with no major difference in most outcomes over a median of 3.2 years. Extended follow-up for mortality is ongoing. Methods: ISCHEMIA participants were randomized to an initial invasive strategy (INV) added to guideline-directed medical therapy or a conservative strategy (CON). Patients with moderate or severe ischemia, ejection fraction ≥35%, and no recent acute coronary syndromes were included...
November 6, 2022: Circulation
https://read.qxmd.com/read/36335915/a-randomized-controlled-trial-comparing-apixaban-to-the-vitamin-k-antagonist-phenprocoumon-in-patients-on-chronic-hemodialysis-the-axadia-afnet-8-study
#18
JOURNAL ARTICLE
Holger Reinecke, Christiane Engelbertz, Rupert Bauersachs, Günter Breithardt, Hans-Herbert Echterhoff, Joachim Gerβ, Karl Georg Haeusler, Bernd Hewing, Joachim Hoyer, Sabine Juergensmeyer, Thomas Klingenheben, Guido Knapp, Lars Christian Rump, Hans Schmidt-Guertler, Christoph Wanner, Paulus Kirchhof, Dennis Goerlich
Background: Non-vitamin K oral anticoagulants (NOACs) have become the standard therapy for preventing stroke and ischemic thromboembolism in most patients with atrial fibrillation (AF). The effectiveness and safety of NOACs in patients on hemodialysis is not well known. Methods: From June 2017 until May 2022, the investigator-initiated, prospective, randomized, open, blinded outcome assessment 'A Safety Study Assessing Oral Anticoagulation with ApiXAban versus Vitamin K-Antagonists in Patients with Atrial Fibrillation and End-Stage Kidney Disease on Chronic HemoDIAlysis Treatment' (AXADIA) trial randomized patients with AF on chronic hemodialysis to either apixaban 2...
November 6, 2022: Circulation
https://read.qxmd.com/read/36335914/apixaban-for-patients-with-atrial-fibrillation-on-hemodialysis-a-multicenter-randomized-controlled-trial
#19
JOURNAL ARTICLE
Sean D Pokorney, Glenn M Chertow, Hussein R Al-Khalidi, Dianne Gallup, Pat Dignaco, Kurt Mussina, Nisha Bansal, Crystal A Gadegbeku, David A Garcia, Samira Garonzik, Renato D Lopes, Kenneth W Mahaffey, Kelly Matsuda, John P Middleton, Jennifer A Rymer, George H Sands, Ravi Thadhani, Kevin L Thomas, Jeffrey B Washam, Wolfgang C Winkelmayer, Christopher B Granger
BACKGROUND: There is no randomized data evaluating the safety or efficacy of apixaban for stroke prevention in patients with end-stage kidney disease (ESKD) on hemodialysis and with atrial fibrillation (AF). METHODS: The RENAL-AF trial was a prospective, randomized, open-label, blinded-outcome evaluation (PROBE) of apixaban versus warfarin in patients receiving hemodialysis with AF and CHA2 DS2 -VASc score ≥2. Patients were randomized 1:1 to apixaban 5mg twice daily (2...
November 6, 2022: Circulation
https://read.qxmd.com/read/36335890/indobufen-or-aspirin-on-top-of-clopidogrel-after-coronary-drug-eluting-stent-implantation-option-a-randomized-open-label-endpoint-blinded-non-inferiority-trial
#20
JOURNAL ARTICLE
Hongyi Wu, Lili Xu, Xin Zhao, Huanyi Zhang, Kang Cheng, Xiaoyan Wang, Manhua Chen, Guangping Li, Jiangnan Huang, Jun Lan, Guanghe Wei, Chi Zhang, Yinman Wang, Juying Qian, Junbo Ge
Background: Dual antiplatelet therapy (DAPT) with aspirin as a background therapy has become the standard care following percutaneous coronary intervention (PCI). However, some adverse non-cardiac effects limited the use of aspirin in clinical practice. Thus, evaluation of pharmacological alternatives to aspirin is attractive. Previous data indicated that indobufen could lessen the unwanted side effects of aspirin while retain the antithrombotic efficacy, but its combination with a P2Y12 inhibitor is still lack of randomized clinical trial (RCT) evidence...
November 6, 2022: Circulation
journal
journal
20069
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.